Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned an average rating of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $43.33.

BCAX has been the subject of several recent analyst reports. TD Cowen initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a report on Tuesday. They set a “buy” rating and a $48.00 price target for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $23.82 on Wednesday. Bicara Therapeutics has a one year low of $18.33 and a one year high of $28.09.

Insider Buying and Selling at Bicara Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the purchase, the director now owns 4,303,418 shares of the company’s stock, valued at $77,461,524. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other Bicara Therapeutics news, major shareholder James E. Flynn purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the transaction, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the transaction, the director now directly owns 4,303,418 shares of the company’s stock, valued at $77,461,524. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Hedge Funds Weigh In On Bicara Therapeutics

An institutional investor recently bought a new position in Bicara Therapeutics stock. First Turn Management LLC acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 562,391 shares of the company’s stock, valued at approximately $14,324,000. Bicara Therapeutics accounts for about 2.3% of First Turn Management LLC’s investment portfolio, making the stock its 24th biggest holding. First Turn Management LLC owned 1.09% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.